Precision for Medicine, a leader in biomarker-driven clinical research, has announced the opening of a new office in Singapore, marking a significant expansion in the Asia-Pacific (APAC) region. This strategic move aims to enhance client support and accelerate regional growth by leveraging Singapore’s central location and advanced infrastructure.
Jing Ping Yeo, Vice President of Clinical Operations, highlighted the importance of this expansion, stating, “This expansion, particularly with our new Singapore hub, signifies a major step in deepening our operational capabilities and localised expertise across APAC.” The new office will support trial oversight and delivery, accelerating site activation and ensuring efficient execution of complex clinical programmes.
The Singapore office is part of Precision’s broader APAC strategy, which includes locations in Mainland China, Hong Kong, India, South Korea, Taiwan, and Australia. With over 500 employees in the region, Precision aims to navigate the complexities of regional drug development and commercialisation more effectively.
For global partners, this expansion positions Precision as a unified contract research organisation (CRO), reducing the complexity of managing multiple partners. For regional clients, it provides the capability to bring innovative therapies to global markets, including the US and Europe.
James Cheong, Senior Vice President of APAC, described the new office as “a strategic pillar in our mission to be the unified partner for precision medicine development, both globally and within the dynamic APAC landscape.” This development underscores Precision’s commitment to integrating global expertise with local insights.
